Inhibition by Heparin of Platelet Accumulation In Vivo

Summary

In vivo platelet aggregation has been studied using a novel, minimally invasive technique. No aggregatory effects of heparin were observed on normal circulating platelets nor was there enhancement of aggregation of platelets during activation by fhtravenous injection of ADP, collagen, PAF acether or thrombin. On the contrary, high doses of heparin were found to inhibit platelet accumulation induced by ADP, collagen or PAF-acether. Inhibition of these responses necessitated doses of heparin in excess of those required for anti-coagulant effects. The present experiments do not establish a mechanism for such inhibition. Extension to other species, including man, is needed before attributing clinical relevance to the present observations.

Keywords

Heparin - Aggregation - In vivo

• References

• 1 Mustard JF, Packham MA. Platelet, thrombosis and drugs. Drugs 1975; 9: 20-76
• 2 Page CP, Paul W, Morley J. An in vivo model for studying platelet aggregation and disaggregation. Thromb Haemostas 1982; 47: 210-213
• 3 Morley J, Page CP, Paul W. The effect of heparin on platelet aggregation in vivo. Br J Pharmacol 1982; 75: 55
• 4 Butler KD, Pay GF, Roberts JM, White AM. The effect of sulphinpyrazone and other drugs on the platelet response during the acute phase of the active arthus reaction in guinea-pigs. Thromb Res 1979; 15: 319-340
• 5 Nelson RA, Jensen J, Gigli I, Tamura N. Methods for the separation, purification and measurement of nine components of haemolytic complement in guinea-pig serum. Immunochemistry 1966; 3: 111-135
• 6 Bishop ON. 1966. Statistics for biology. Longmans;
• 7 Page CP, Paul W, Morley J. In vivo aggregation of guinea-pig platelets in response to synthetic platelet activating factor (PAF-acether). Agents Actions 1983; 13: 506-507
• 8 Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. Ann Intern Med 1974; 80: 477-481
• 9 Bell WR, Anderson N, Anderson AD. Heparin induced coagulopathy. J Lab Clin Med 1977; 89: 741-750
• 10 Eika C. Platelet refractory state induced by heparin. Scand J Haematol 1972; 9: 665-672
• 11 Faduda T, Tatsumi Y, Tatsumi N, Kimura Y, Maeda H, Okuda K. Effects of heparin on platelet function. OCMJ 1981; 27: 47-54
• 12 Anderson WH, Mohammed SF, Chuang AY K, Mason RG. Heparin potentiates synthesis of thromboxane A₂ in human platelets. Advances in Prostaglandin and Thromboxane Research. Sammuelson B, Ramwell PW, Paoletti R. (Eds.) Raven Press; New York: 1980. 6 287-291
• 13 Mohammed SF, Anderson WH, Smith JB, Chuang HY K, Mason RG. Effects of heparin on platelet aggregation and release and thromboxane A₂ production. Am J Pathol 1981; 104: 132-141
• 14 Koth W, Nowak G, Markwardt F. Monitoring of microthrombosis in experimental animals by continuous recording of ¹²⁵I-fibrin deposits and ⁵¹Cr-labelled platelets in the lungs. Acta Biol Med Germ 1980; 39: 157-162
• 15 Niewiarowski S, Bankowski E, Rogowicka I. Studies on the adsorption and activation of the Hageman factor (Factor XII) by collagen and elastin. Thrombos Diathes Haemorrh 1965; 14: 387-400
• 16 Wilner GD, Nossel HL, Leroy ED. Activation of Hageman factor by collagen. J Clin Invest 1968; 47: 2608-2615
• 17 Walsh PN. Different requirements for intrinsic factor-Xa forming activity and platelet factor 3 activity and their relationship to platelet aggregation and secretion. Br J Haematol 1978; 40: 311-331
• 18 Henson PM, Landas RR. Activation of platelets by platele-tactivating factor (PAF) derived from IgE-sensitised basophils IV PAF does not activate platelet factor 3 (PF₃). Br J Haematol 1976; 34: 269-282